Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans-Reference-Cited by-同舟云学术

Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans

Published:2023-01-13 Issue:4 Volume:51 Page:451-463
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Bhattacharya Chandrali,Sandinge Ann-Sofie,Bragg Ryan A.,Heijer Maria,Yan Jingjing,Andersson Linda C.,Jurva Ulrik,Pelay-Gimeno Marta,Vaes Wouter H.J.,de Ligt Rianne A.F.,Gränfors Malin,Amilon Carl,Lindstedt Eva-Lotte,Menakuru Somasekhara R.,Garkaviy Pavlo,Weidolf Lars,Gopaul V. Sashi

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference39 articles.

1. National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017;Agarwal;JAMA Cardiol,2021

2. Management of chronic heart failure in the older population;Azad;J Geriatr Cardiol,2014

3. Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes

4. Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches

5. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early clinical drug product shelf-life setting using accelerated predictive stability and metabolite data for impurity qualification: A case study;Journal of Pharmaceutical Sciences;2024-09

2. The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat;British Journal of Clinical Pharmacology;2024-08-12

3. Biotransformation research advances – 2023 year in review;Drug Metabolism Reviews;2024-07-11

4. The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses;Pharmacology Research & Perspectives;2024-03-06

5. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans;Drug Metabolism and Disposition;2023-01-18